SCHEMBL7090969

SCHEMBL7090969

CSc1ccc(C(O)C(=O)c2ccc(Cl)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.49
AKR1C2 P52895 1/20 0.49
AKR1C1 Q04828 1/20 0.49
CES2 O00748 4/20 0.46
CES1 P23141 4/20 0.46
LMNA P02545 2/20 0.44
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
TSHR P16473 4/20 0.42
HSD17B10 Q99714 2/20 0.42
PLK1 P53350 1/20 0.42
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
BRD4 O60885 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11186384 0.92 CES2 (0.53) AKR1C3AKR1C2CES2CES1LMNA
SCHEMBL1546852 0.86 CES2 (0.58) CES2CES1LMNAALDH1A1KDM4E
SCHEMBL7087847 0.85 CES2 (0.47) AKR1C3AKR1C2CES2CES1LMNA
SCHEMBL11753507 0.84 AKR1C3 (0.49) AKR1C3AKR1C2AKR1C1CES2CES1
SCHEMBL14507322 0.84 AKR1C3 (0.49) AKR1C3AKR1C2AKR1C1CES2CES1
SCHEMBL11749450 0.84 AKR1C3 (0.49) AKR1C3AKR1C2AKR1C1CES2CES1
SCHEMBL7087822 0.84 CES2 (0.50) CES2CES1LMNAALDH1A1KDM4E
SCHEMBL8148223 0.84 CES2 (0.50) CES2CES1LMNAALDH1A1KDM4E
SCHEMBL7088579 0.83 LMNA (0.67) AKR1C3AKR1C2AKR1C1CES2CES1
SCHEMBL7087910 0.83 TSHR (0.42) CES2CES1TSHRPLK1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US disclosed
EP-0772601-B1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-18 EP disclosed
US-6426360-B1 ANTIARTHRITIC AGENTS G D SEARLE & CO. 2002-07-30 US disclosed
EP-1211244-A2 4,5-substitued imidazolyl compounds for the treatment of inflammation G.D. Searle & Co. (US) 2002-06-05 EP disclosed
US-5620999-A ANTIARTHRITIC, ANALGESIC AND ANTIPYRATIC AGENT G.D. SEARLE & CO. 1997-04-15 US disclosed
WO-1996003387-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 AKR1C3 368/4885AKR1C2 423/4885AKR1C1 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.